{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:27:01Z","timestamp":1793888821107,"version":"4.8.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Erdheim-Chester disease (ECD) is characterized by the infiltration of tissues by foamy CD68+CD1a\u2212 histiocytes, with 1500 known cases since 1930. Mutations activating the MAPK pathway are found in more than 80% of patients with ECD, mainly the BRAFV600E activating mutation in 57% to 70% of cases, followed by MAP2K1 in close to 20%. The discovery of BRAF mutations and of other MAP kinase pathway alterations, as well as the co-occurrence of ECD with LCH in 15% of patients with ECD, led to the 2016 revision of the classification of histiocytoses in which LCH and ECD belong to the \u201cL\u201d group. Both conditions are considered inflammatory myeloid neoplasms. Ten percent of ECD cases are associated with myeloproliferative neoplasms and\/or myelodysplastic syndromes. Some of the most striking signs of ECD are the long bone involvement (80%-95%), as well as the hairy kidney appearance on computed tomography scan (63%), the coated aorta (40%), and the right atrium pseudo-tumoral infiltration (36%). Central nervous system involvement is a strong prognostic factor and independent predictor of death. Interferon-\u03b1 seems to be the best initial treatment of ECD. Since 2012, more than 200 patients worldwide with multisystem or refractory ECD have benefitted from highly effective therapy with BRAF and MEK inhibitors. Targeted therapies have an overall, robust, and reproducible efficacy in ECD, with no acquired resistance to date, but their use may be best reserved for the most severe manifestations of the disease, as they may be associated with serious adverse effects and as-yet-unknown long-term consequences.<\/jats:p>","DOI":"10.1182\/blood.2019002766","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T18:19:52Z","timestamp":1582827592000},"page":"1311-1318","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":221,"title":["Erdheim-Chester disease"],"prefix":"10.1182","volume":"135","author":[{"given":"Julien","family":"Haroche","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Service de M\u00e9decine Interne 2, Maladies Auto-Imunes et Syst\u00e9miques, Centre National de R\u00e9f\u00e9rence des Histiocytoses, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7610-4995","authenticated-orcid":false,"given":"Fleur","family":"Cohen-Aubart","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Service de M\u00e9decine Interne 2, Maladies Auto-Imunes et Syst\u00e9miques, Centre National de R\u00e9f\u00e9rence des Histiocytoses, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Service de M\u00e9decine Interne 2, Maladies Auto-Imunes et Syst\u00e9miques, Centre National de R\u00e9f\u00e9rence des Histiocytoses, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2020041611582088400_B1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF01942684","article-title":"\u00dcber Lipoidgranulomatose","volume":"279","author":"Chester","year":"1930","journal-title":"Virchows Arch Pathol Anat"},{"issue":"11","key":"2020041611582088400_B2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2020041611582088400_B3","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2020041611582088400_B4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"issue":"19","key":"2020041611582088400_B5","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease","volume":"124","author":"Emile","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020041611582088400_B6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020041611582088400_B7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease","volume":"33","author":"Haroche","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020041611582088400_B8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"7749","key":"2020041611582088400_B9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"22","key":"2020041611582088400_B10","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020041611582088400_B11","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.25055","article-title":"Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort","volume":"93","author":"Cohen-Aubart","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"2020041611582088400_B12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","article-title":"The clinical spectrum of Erdheim-Chester disease: an observational cohort study","volume":"1","author":"Estrada-Veras","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2020041611582088400_B13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020041611582088400_B14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1750-1172-8-137","article-title":"Erdheim-Chester disease: a comprehensive review of the literature","volume":"8","author":"Mazor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2020041611582088400_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.02.004","article-title":"Erdheim-Chester disease: a systematic review","volume":"95","author":"Cives","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2020041611582088400_B16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-Chester disease","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"10","key":"2020041611582088400_B17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/MPH.0b013e3181b76827","article-title":"Erdheim-Chester disease in childhood: a challenging diagnosis and treatment","volume":"31","author":"Tran","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11 Pt 2","key":"2020041611582088400_B18","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.lpm.2007.04.032","article-title":"[Erdheim-Chester disease]","volume":"36","author":"Haroche","year":"2007","journal-title":"Presse Med"},{"issue":"10","key":"2020041611582088400_B19","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/art.24848","article-title":"18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease","volume":"60","author":"Arnaud","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2020041611582088400_B20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.md.0000145368.17934.91","article-title":"Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review","volume":"83","author":"Haroche","year":"2004","journal-title":"Medicine (Baltimore)"},{"issue":"25","key":"2020041611582088400_B21","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1161\/CIRCULATIONAHA.108.825075","article-title":"Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients","volume":"119","author":"Haroche","year":"2009","journal-title":"Circulation"},{"key":"2020041611582088400_B22","article-title":"BRAF V600E mutation correlates with cardiac involvement assessed by heart imaging in a monocentric series of 205 patients with Erdheim-Chester disease [abstract]","volume":"3","author":"Bravetti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020041611582088400_B23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.urology.2013.10.023","article-title":"Urologic manifestations of Erdheim-Chester disease","volume":"84","author":"Yelfimov","year":"2014","journal-title":"Urology"},{"issue":"1","key":"2020041611582088400_B24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(17)36011-1","article-title":"Successful management of bilateral xanthogranulomatous pyelonephritis by bilateral partial nephrectomy","volume":"149","author":"Per\u00e9z","year":"1993","journal-title":"J Urol"},{"issue":"11","key":"2020041611582088400_B25","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00330-010-1830-7","article-title":"Erdheim-Chester disease: CT findings of thoracic involvement","volume":"20","author":"Brun","year":"2010","journal-title":"Eur Radiol"},{"issue":"11","key":"2020041611582088400_B26","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/art.27672","article-title":"Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature","volume":"62","author":"Arnaud","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2020041611582088400_B27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1210\/jc.2015-3357","article-title":"Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease","volume":"101","author":"Courtillot","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020041611582088400_B28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2015.11.007","article-title":"Cutaneous manifestations of Erdheim-Chester disease (ECD): clinical, pathological, and molecular features in a monocentric series of 40 patients","volume":"74","author":"Chasset","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2020041611582088400_B29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00415-006-0160-9","article-title":"Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature","volume":"253","author":"Lachenal","year":"2006","journal-title":"J Neurol"},{"issue":"2","key":"2020041611582088400_B30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1148\/radiol.10090320","article-title":"Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings","volume":"255","author":"Drier","year":"2010","journal-title":"Radiology"},{"issue":"10","key":"2020041611582088400_B31","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","article-title":"CNS involvement and treatment with interferon-\u03b1 are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020041611582088400_B32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/01676830.2016.1176211","article-title":"Erdheim-Chester disease with orbital involvement: Case report and ophthalmic literature review","volume":"35","author":"Merritt","year":"2016","journal-title":"Orbit"},{"issue":"2","key":"2020041611582088400_B33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1572-0241.2006.00893.x","article-title":"Biliary manifestation of Erdheim-Chester disease mimicking Klatskin\u2019s carcinoma","volume":"102","author":"Gundling","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2020041611582088400_B34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.humpath.2014.10.005","article-title":"Erdheim-Chester disease involving the breast--a rare but important differential diagnosis","volume":"46","author":"Guo","year":"2015","journal-title":"Hum Pathol"},{"issue":"11","key":"2020041611582088400_B35","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/jcp.2004.018481","article-title":"Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature","volume":"57","author":"Sheu","year":"2004","journal-title":"J Clin Pathol"},{"issue":"10","key":"2020041611582088400_B36","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2010-10-313510","article-title":"Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2020041611582088400_B37","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1002\/art.22280","article-title":"Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis","volume":"54","author":"Stoppacciaro","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2020041611582088400_B38","doi-asserted-by":"crossref","first-page":"e1440929","DOI":"10.1080\/2162402X.2018.1440929","article-title":"The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease","volume":"7","author":"Pacini","year":"2018","journal-title":"OncoImmunology"},{"issue":"6","key":"2020041611582088400_B39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/rheumatology\/kep461","article-title":"Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis","volume":"49","author":"Dagna","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2020041611582088400_B40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","article-title":"Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases","volume":"75","author":"Veyssier-Belot","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"9976","key":"2020041611582088400_B41","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"issue":"9506","key":"2020041611582088400_B42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"issue":"61","key":"2020041611582088400_B43","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.18632\/oncotarget.27304","article-title":"The multifaceted anti-cancer effects of BRAF-inhibitors","volume":"10","author":"Croce","year":"2019","journal-title":"Oncotarget"},{"issue":"3","key":"2020041611582088400_B44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM199407213310303","article-title":"Langerhans\u2019-cell histiocytosis (histiocytosis X)--a clonal proliferative disease","volume":"331","author":"Willman","year":"1994","journal-title":"N Engl J Med"},{"issue":"10","key":"2020041611582088400_B45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2020041611582088400_B46","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.3324\/haematol.2018.201194","article-title":"Highly sensitive methods are required to detect mutations in histiocytoses","volume":"104","author":"Melloul","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"2020041611582088400_B47","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/ATVBAHA.118.310803","article-title":"Hypoalphalipoproteinemia and BRAFV600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease","volume":"38","author":"Cohen-Aubart","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"2020041611582088400_B48","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","article-title":"Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation","volume":"124","author":"Hervier","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020041611582088400_B49","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2019.216937","article-title":"Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1","volume":"105","author":"Razanamahery","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2020041611582088400_B50","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2017-01-761718","article-title":"High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis","volume":"130","author":"Papo","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020041611582088400_B51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2016-12-757377","article-title":"Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem\/progenitor cells","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020041611582088400_B52","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S1470-2045(17)30031-1","article-title":"Histiocytoses: emerging neoplasia behind inflammation","volume":"18","author":"Haroche","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"2020041611582088400_B53","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/art.22165","article-title":"Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients","volume":"54","author":"Haroche","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2020041611582088400_B54","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2015-09-672667","article-title":"Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease","volume":"127","author":"Cohen-Aubart","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020041611582088400_B55","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/annrheumdis-2017-212678","article-title":"Efficacy of infliximab in the treatment of Erdheim-Chester disease","volume":"77","author":"Cohen-Aubart","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"2020041611582088400_B56","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2020041611582088400_B57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET Study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"2020041611582088400_B58","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.14284","article-title":"Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease","volume":"180","author":"Cohen Aubart","year":"2018","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/16\/1311\/1724169\/bloodbld2019002766c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/16\/1311\/1724169\/bloodbld2019002766c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T15:10:52Z","timestamp":1587049852000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/16\/1311\/452578\/ErdheimChester-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":58,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,4,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002766","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}